Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 15/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567835 | 1.00 | S1PR1 (0.52) | S1PR1S1PR3S1PR4S1PR5PPARG | |
| SCHEMBL1786493 | 0.89 | S1PR1 (0.64) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1567290 | 0.89 | S1PR1 (0.64) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL2178316 | 0.82 | S1PR1 (0.54) | S1PR1S1PR4S1PR5 | |
| SCHEMBL1567396 | 0.75 | S1PR1 (0.80) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1567394 | 0.75 | S1PR1 (0.80) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1567771 | 0.75 | S1PR1 (0.82) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1567772 | 0.75 | S1PR1 (0.82) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL12555298 | 0.75 | S1PR1 (0.82) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1788751 | 0.75 | S1PR1 (0.82) | S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3272736-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2018-01-24 | — | — | EP | claimed |
| EP-3138835-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | claimed |
| EP-2514743-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2016-12-14 | — | — | EP | claimed |
| EP-2695615-A2 | Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation | Novartis AG (CH) | 2014-02-12 | — | — | EP | claimed |
| EP-2514743-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2012-10-24 | — | — | EP | claimed |
| JP-4700616-B2 | — | — | 2011-06-15 | — | — | JP | claimed |
| US-20110124620-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODUATORS AND THEIR USE TO TREAT MUSCLE INFLAMMATION | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | claimed |
| US-20090036423-A1 | IMMUNOSUPPRESANT COMPOUNDS AND COMPOSITIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2009-02-05 | — | — | US | claimed |
| EP-1633336-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-10-29 | — | — | EP | claimed |
| EP-1633336-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-15 | — | — | EP | claimed |
| US-20050014728-A1 | Immunosuppressant compounds and compositions | IRM LLC | 2005-01-20 | — | — | US | claimed |
| WO-2004103306-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-02 | — | — | WO | claimed |
| EP-3272736-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| EP-3138835-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138835-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| EP-2514743-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2016-12-14 | — | — | EP | disclosed |
| EP-1633336-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-10-29 | — | — | EP | disclosed |
| EP-1633336-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-15 | — | — | EP | disclosed |
| US-20050014728-A1 | Immunosuppressant compounds and compositions | IRM LLC | 2005-01-20 | — | — | US | disclosed |
| WO-2004103306-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014728-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885S1PR4 211/4885 |
| US-20090036423-A1 | IMMUNOSUPPRESANT COMPOUNDS AND COMPOSITIONS | EDNRA, NFATC1, FCGR1A | S1PR1 163/4885S1PR3 189/4885S1PR4 278/4885 |
| US-20110124620-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODUATORS AND THEIR USE TO TREAT MUSCLE INFLAMMATION | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.